NCT00514969已完成2 期
Protein-Tyrosine Kinase Inhibitor (STI571) for Treatment of Patients With Ph+ Chronic Myeloid Leukemia in Accelerated and Blastic Phase. A Phase II Study
University of Bologna1 个研究点 分布在 1 个国家开始时间: 2000年8月1日最近更新:
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 试验地点
- 1
- 主要终点
- To determine the rate of hematological response lasting * 4 weeks in adult patients with Ph chromosome positive CML in accelerated and blastic phase
研究概览
简要总结
This is a phase II, multi-center, open-label, non-randomized trial. During Part 1 of the trial, patients will receive once daily oral administration of STI571 at a dose of 600 mg for 24 weeks. After completing 24 weeks of therapy, patients may be eligible to receive additional therapy during Part 2 of the trial provided that, in the opinion of the investigator, the patient has benefited from treatment with STI571 and in the absence of safety concerns. During Part 2 (which is of indefinite duration), patients will continue to receive STI571 on a daily basis until either death, the development of intolerable toxicity or the investigator feels it is no longer in the patient's best interest to continue therapy, whichever comes first.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female patients * 18 years of age
- •Accelerated phase of CML defined as the presence of one or more of the following:
- •percentage of blasts in blood or bone marrow * 15% but < 30%
- •percentage of blasts plus promyelocytes in the peripheral blood or bone marrow * 30% (providing that < 30% blasts are present in the bone marrow)
- •peripheral basophils * 20%
- •thrombocytopenia < 100 x 109/L unrelated to therapy These criteria must be met within 4 weeks of administration of first dose of trial treatment.
- •Blastic phase of CML defined as the presence of one or more of the following:
- •percentage of blasts in blood or bone marrow * 30%
- •percentage of blasts and promyelocytes in blood or bone marrow * 50%
- •documented extramedullary blast involvement (skin, lymph node, bone, lung).
- •Voluntary written informed consent.
排除标准
- •Patients of childbearing potential wihout a negative pregnancy test prior to the initiation of study drug. Barrier contraceptive precautions are to be used throughout the trial in both sexes.
- •Patients with an ECOG Performance Status Score ** 3 (see Section 7.2.1)
- •Creatinine levels more than 2 x's the ULN at the laboratory where the analysis was performed.
- •Total serum bilirubin more than 1.5 x's the upper limit of the normal range (ULN) at the laboratory where the analyses were performed; in patients with clinically suspected leukemic involvement of the liver, total bilirubin more than 3 x's the ULN
- •AST (SGOT) or ALT (SGPT) more than 3 x's the upper limit of the normal range (ULN) at the laboratory where the analyses were performed; in patients with clinically suspected leukemic involvement of the liver, AST and ALT more than 5 x's the ULN
- •Patients receiving treatment with interferon-alpha within 48 hours of Day
- •Patients receiving treatment with hydroxyurea within 24 hours of Day 1
- •Patients receiving treatment with homoharringtonine within 14 days of Day 1
- •Patients receiving treatment with low-dose cytosine arabinoside (< 30 mg/m2 every 12 to 24 hours administered daily) within seven days of Day 1
- •Patients receiving treatment with moderate dose cytosine arabinoside (100-200 mg/m2 for 5 to 6 days) within 14 days of Day
- •Patients receiving treatment with high-dose cytosine arabinoside (1-3 g(m2 every 12 to 24 hours for six to 12 doses) within 28 days of Day
- •Patients receiving anthracyclines, mitoxantrone, etoposide, methotrexate or cyclophosphamide within 21 days of Day
- •Patients receiving busulfan within six weeks of Day
- •Patients receiving anti-leukemic agents not included in Exclusion Criteria 6-13 should not begin treatment with STI571 until sufficient time has elapsed for potential recovery to have occurred in the nadir in blood counts. In practice, a full recovery of blood counts may not be possible due to progression of the underlying disease.
- •Patients receiving any hematopoietic stem cell transplantation and who have not achieved full hematopoietic recovery following the transplant
- •Patients receiving any other investigational agents within 28 days of Day
- •Patients with Grade ¾ cardiac disease.
- •Patients with any serious concomitant medical condition
- •Patients with a history of non-compliance to medical regimens or who are considered potentially unreliable.
- •Patients with a prior diagnosis of accelerated or blastic phase who are in remission and do not fit inclusion criteria, are not eligible.
- •Patients who are likely to be submitted to any procedure of stem cell transplantation before the end of the treatment (6 months), are not eligible.
结局指标
主要结局
To determine the rate of hematological response lasting * 4 weeks in adult patients with Ph chromosome positive CML in accelerated and blastic phase
次要结局
- duration of hematological response and overall survival, cytogenetic response and safety
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Protein-Tyrosine Kinase Inhibitor (STI571) for Treatment of Patients With Ph+ Chronic Myeloid LeukemiaChronic Myeloid LeukemiaNCT00511303University of Bologna200
招募中
2 期
A Phase II Study of Zanubrutinib, Lenalidomide Plus R-CHOP as the First-line Treatment for Diffused Large B-cell LymphomaNon Hodgkin LymphomaDiffuse Large B Cell LymphomaNCT05200312The First Affiliated Hospital with Nanjing Medical University36
已完成
1 期
A Phase I/II Study to Assess the Safety and Efficacy of TKI258 for the Treatment of Refractory Advanced/Metastatic Renal Cell CancerAdvanced/ Metastatic Renal Cell CancerNCT00715182Novartis Pharmaceuticals87
已完成
1 期
A Phase 2 Trial of MP0250 Plus Bortezomib + Dexamethasone in Patients With Multiple MyelomaMultiple Myeloma in RelapseNCT03136653Molecular Partners AG33
尚未招募
2 期
SSOSS Trial (Sunflower Seed Oil in Small babies Study)PACTR202405729585049Mbale Clinical Research Institute1,242